We are live on ! Find out more
KRYS icon

Krystal Biotech
KRYS

13 hedge funds and large institutions have $34M invested in Krystal Biotech in 2017 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% more capital invested

Capital invested by funds: $31.3M → $34M (+$2.72M)

0% more funds holding

Funds holding: 13 → 13 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

0.99% less ownership

Funds ownership: 32.6% → 31.6% (-0.99%)

Holders
13
Holders Change
–
Holders Change %
0%
% of All Funds
0.29%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
5
Increased
3
Reduced
–
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$743K
2
AG
Artal Group
Luxembourg
+$501K
3
Millennium Management
Millennium Management
New York
+$253K
4
Squarepoint
Squarepoint
New York
+$108K
5
TCP
Tourbillon Capital Partners
New York
+$23.5K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$534K
2
TSS
Two Sigma Securities
New York
-$137K
3
UBS Group
UBS Group
Switzerland
-$26K
4
FMA
FNY Managed Accounts
New York
-$23K
5
CCA
Catalyst Capital Advisors
New York
-$5K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$12.6M – – –
RCM
2
RA Capital Management
Massachusetts
$7.36M – – –
HCM
3
Highbridge Capital Management
New York
$3.16M – – –
KCM
4
Knoll Capital Management
Florida
$3.16M – – –
TCP
5
Tourbillon Capital Partners
New York
$2.65M +$23.5K +2,348 +0.9%
BBA
6
Baker Bros. Advisors
New York
$2.1M – – –
AG
7
Artal Group
Luxembourg
$1.58M +$501K +50,000 +50%
Vanguard Group
8
Vanguard Group
Pennsylvania
$779K +$743K +74,100 New
Millennium Management
9
Millennium Management
New York
$266K +$253K +25,268 New
Goldman Sachs
10
Goldman Sachs
New York
$232K +$22.4K +2,236 +11%
Squarepoint
11
Squarepoint
New York
$114K +$108K +10,800 New
KBC Group
12
KBC Group
Belgium
$11K +$10K +1,000 New
BlackRock
13
BlackRock
New York
$8K +$7.99K +797 New
SM
14
Sabby Management
Florida
– -$534K -53,558 Closed
TSS
15
Two Sigma Securities
New York
– -$137K -13,786 Closed
UBS Group
16
UBS Group
Switzerland
– -$26K -2,562 Closed
FMA
17
FNY Managed Accounts
New York
– -$23K -2,400 Closed
CCA
18
Catalyst Capital Advisors
New York
– -$5K -465 Closed

KRYS Hedge Fund Activity: Q4 2017 in Review

13 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q4 2017, worth a combined $34M — up 8.7% from $31.3M a quarter earlier.

Fund positioning in KRYS was balanced in Q4 2017: 5 funds opened new positions, 5 closed out, 3 added to existing stakes and 0 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $743K. The largest seller was Sabby Management, exiting entirely with an estimated $534K sold.

  • 13 institutional investors held Krystal Biotech (KRYS) as of Q4 2017, unchanged from Q3 2017.
  • Funds reported $34M of Krystal Biotech stock for Q4 2017, up 8.7% quarter-over-quarter.
  • 5 funds opened new Krystal Biotech positions in Q4 2017 and 5 closed out, a net change of 0 holders.
  • The largest Krystal Biotech buyer in Q4 2017 was Vanguard Group, an estimated $743K added.
  • The largest Krystal Biotech seller in Q4 2017 was Sabby Management, an estimated $534K sold.

Based on aggregated 13F filings for Q4 2017.